<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-154870" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Calcium Deposition and Other Renal Crystal Diseases</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simhadri</surname>
            <given-names>Prathap Kumar</given-names>
          </name>
          <aff>Advent Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prathap Kumar Simhadri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-154870.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Crystals are groups of ions, atoms, and molecules that can form into homogeneous solids and have a fixed distance between the constituent parts, creating an orderly, repeating 3-dimensional pattern. The molecular components of crystals are filtered from the plasma through the kidneys and concentrated in the renal tubules. The kidneys are a primary site of crystalline deposition, receiving 25% of total cardiac output.</p>
        <p>These deposits primarily occur in the renal tubules, interstitium, or both. They are associated with the development of acute kidney injury (AKI) or progressive chronic kidney disease (CKD), which can present with microscopic hematuria, crystalluria, and sub-nephrotic range proteinuria.<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r3">[3]</xref></p>
      </sec>
      <sec id="article-154870.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Urinary and renal crystalline disorders are broadly categorized by underlying etiology into four major groups.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Calcium oxalate and calcium phosphate crystallopathy</p>
          </list-item>
          <list-item>
            <p>Paraproteinemia-related crystal deposition diseases&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Crystal deposition secondary to metabolic and inherited disorders&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drug-induced crystal deposition disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-154870.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Autosomal recessive crystalline deposition diseases include the following: primary hyperoxaluria; 2,8 dihydroxy adenine (2,8 DHA) crystalluria; cystinuria, and cystinosis. These diseases are more prevalent in areas with consanguineous marriages.</p>
        <p>Primary hyperoxaluria type 1 (PH1) accounts for 1% to 2% of end-stage renal disease (ESRD) in children. PH1 has an incidence of 1 in 120,000 live births in Europe.</p>
        <p>Cystinosis occurs approximately once in every 100,000 to 200,000 live births.<xref ref-type="bibr" rid="article-154870.r5">[5]</xref>&#x000a0;It accounts for 5% of ESRD in children.</p>
        <p>Cystinuria accounts for about 1% to 2% of renal stones in adults.<xref ref-type="bibr" rid="article-154870.r6">[6]</xref></p>
        <p>Adenine phosphoribosyl transferase deficiency (APRT), which is the cause of 2,8 DHA crystalline nephropathy, has an estimated prevalence of about 400 worldwide. While very rare, most cases are found in France, Iceland, and Japan.<xref ref-type="bibr" rid="article-154870.r7">[7]</xref>&#x000a0;</p>
        <p>Multiple myeloma is diagnosed in an estimated 34,920 people in the US and approximately 588,161 people worldwide each year.</p>
        <list list-type="bullet">
          <list-item>
            <p>Myeloma accounts for 1% of all cancers and 10% of all hematological malignancies.<xref ref-type="bibr" rid="article-154870.r8">[8]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with multiple myeloma, about 50% will develop renal disease.</p>
          </list-item>
          <list-item>
            <p>Myeloma cast nephropathy is the most common cause of acute kidney injury in these patients.<xref ref-type="bibr" rid="article-154870.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-154870.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Crystal deposition leads to tubular obstruction, inflammation, and intracellular inclusion. As the crystals are phagocytosed by lysosomes of the renal tubular cells, they release cathepsin-B and other cell death pathway mediators, leading to eventual necroptosis of the cell.</p>
        <p>Renal tubular cell necrosis stimulates the inflammatory pathway leading to further cell damage, activation of Toll-like receptors, induction of NLRP3 inflammasome activity, and secretion of interleukin 1b, which further leads to increased transcription and expression of several inflammatory cytokines.&#x000a0;</p>
        <p>Activation of the inflammatory cascade contributes to the robust inflammation within the tubulointerstitium,&#x000a0;which plays a key&#x000a0;role in the development of acute and chronic kidney disease in renal crystallopathies.<xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r3">[3]</xref></p>
        <p>Hyperoxaluria and calcium oxalate crystal deposition in the vagina has been proposed as possible etiology of vulvodynia in women. While theoretically possible, the scientific data does not support this conclusion except in rare, anecdotal cases.<xref ref-type="bibr" rid="article-154870.r10">[10]</xref><xref ref-type="bibr" rid="article-154870.r11">[11]</xref><xref ref-type="bibr" rid="article-154870.r12">[12]</xref><xref ref-type="bibr" rid="article-154870.r13">[13]</xref><xref ref-type="bibr" rid="article-154870.r14">[14]</xref></p>
      </sec>
      <sec id="article-154870.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p><bold>Calcium oxalate</bold> crystals are deposited in the renal tubules, interstitium, or both, leading to AKI, oxalate nephropathy, and progressive CKD.</p>
        <p>The prevalence of oxalate nephropathy varies across different studies. The prevalence was about 1% on native kidney biopsies in one Belgian series but reached up to 4% in a biopsy series done in the New York metro area.<xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r15">[15]</xref></p>
        <p>Oxalate is the ionized form of oxalic acid. The average person consumes about 100 mg to 140 mg of oxalate daily. Only 5% to 15% of dietary oxalate is absorbed in the intestinal tract. Most dietary oxalate binds to ingested calcium and is excreted harmlessly as calcium oxalate in the stool. Oxalate is also degraded by colonic bacteria such as <italic toggle="yes">Oxalobacter formigenes</italic>. The liver produces&#x000a0;60% to 80% of plasma oxalate, and dietary absorption contributes to the rest.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p>Oxalate has no physiological role in the human body. Most of the absorbed oxalate gets filtered and excreted unchanged by the glomerulus and is actively secreted by the proximal convoluted tubules into the urine.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;&#x000a0;</p>
        <p>The urinary oxalate excretion varies depending on daily oral intake; oxalate excretion exceeding 40 mg per 24 hours is generally consistent with hyperoxaluria. Hyperoxaluria is an independent risk factor for the progression of chronic kidney disease, even in patients with no evidence of oxalate nephropathy.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;</p>
        <p>Systemic levels of oxalate increase once the GFR drops below 30 ml/min, which leads to extrarenal calcium oxalate deposits in other organs, such as the bones, skin, central nervous system, retina, and cardiovascular system, consistent with systemic oxalosis.</p>
        <p>Calcium oxalate crystals are translucent when viewed by standard light microscopy and strongly birefringent on polarized microscopy.</p>
        <p>There are two crystalline forms of calcium oxalate. Calcium oxalate monohydrate can appear dumbbell-shaped. Calcium oxalate dihydrate looks like two four-sided pyramids connected at the bases and is also sometimes described as envelope-shaped. Calcium oxalate monohydrate stones are tough and difficult to break down, while calcium oxalate dihydrate calculi are quite fragile. Many stones and crystals will have varying percentages of each.</p>
        <p>There are three categories of hyperoxaluria: primary (genetic), secondary (acquired), and enteric.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p><bold>Primary hyperoxaluria</bold> is a group of rare autosomal recessive disorders associated with excess oxalate production by the liver. The high oxalate load exceeds the excretion capacity of the kidneys and causes precipitation, leading to recurrent kidney stones and oxalate nephropathy. Patients with primary hyperoxaluria have abnormally elevated urinary oxalate excretion, typically in the range of greater than 100 mg/day, but a threshold of greater than 75 mg/day is generally used to differentiate primary and secondary hyperoxalurias.&#x000a0;For more information on primary and secondary hyperoxaluria, please see our companion StatPearls reference article on "Hyperoxaluria."<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p>Primary hyperoxaluria is a common cause of ESRD in younger patients. It has three subgroups based on the specific type of enzymatic defect.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref>&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1 Primary Hyperoxaluria (PH1) is the most common and severe type of primary hyperoxaluria.
<list list-type="bullet"><list-item><p>The deficiency of pyridoxal-dependent, alanine glyoxal transferase in hepatic peroxisomes leads to increased oxalate production from glyoxylate in the cytoplasm of liver cells.</p></list-item><list-item><p>The AGXT gene encodes AGT, and more than 200 mutations of the AGXT gene are known to cause PH1.<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;</p></list-item><list-item><p>Patients with PH1 have recurrent calcium oxalate kidney stones, rapidly progressive chronic kidney disease, and can progress to ESRD.</p></list-item><list-item><p>The median onset of ESRD is 5.5 years, and most develop renal failure in the first three decades of life; some patients have delayed presentation in adulthood with occasional or recurrent calcium oxalate kidney stones as their only clinical manifestation.<xref ref-type="bibr" rid="article-154870.r2">[2]</xref></p></list-item><list-item><p>Primary hyperoxaluria should be considered in children with kidney stones or nephrocalcinosis and adults with recurrent calcium oxalate kidney stones.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type 2 Primary Hyperoxaluria (PH2) is caused by a glyoxylate hydroxypyruvate reductase (GRHPR) deficiency, leading to excess glyoxylate accumulation, an immediate oxalate precursor.
<list list-type="bullet"><list-item><p>This enzyme is expressed in multiple other tissues in addition to the liver.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p></list-item><list-item><p>Patients with PH2 disease can have progressive CKD and recurrent calcium oxalate nephrolithiasis, and recent data suggest that these can also progress to ESRD, requiring renal transplantation.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type 3 Primary Hyperoxaluria (PH3) is caused by the deficiency of 4-hydroxy-2-oxoglutarate (HOGA).
<list list-type="bullet"><list-item><p>This can lead to excess oxalate production in the liver but is also expressed in the kidneys.</p></list-item><list-item><p>Progression to CKD/ESRD has yet to be documented with PH3.</p></list-item><list-item><p>The exact mechanism of how a deficiency of the enzyme HOGA leads to excess oxalate production is unclear.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Secondary hyperoxaluria</bold> causing oxalate nephropathy is characterized by increased oxalate levels due to various secondary causes that include increased dietary intake of oxalate-containing foods, increased intestinal absorption of oxalate in a setting of fat malabsorption (enteric hyperoxaluria), increased intake of oxalate precursors, and alteration of intestinal microbial flora.</p>
        <p>The prevalence of this condition varies from 1% to 4% on native kidney biopsies. Patients with oxalate nephropathy showed progressive advanced CKD (after other etiologies of renal failure were excluded) and had deposition of calcium oxalate crystals within the tubular epithelial cells, lumens, and occasionally in the interstitium; most of these patients had a hyperoxaluria-enabling condition.<xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
        <p>Excess intake of oxalate precursor substances like ethylene glycol and vitamin C is known to cause crystalline oxalate nephropathy. Cases of vitamin C-induced oxalate nephropathy are associated with mega doses of vitamin C intake,&#x000a0;such as those seen during the&#x000a0;COVID-19 pandemic. Cases can also occur with the intake of other oxalate precursors such as methoxyflurane (a general anesthetic), ethylene glycol, and naftidrofuryl oxalate (a vasodilator used in the treatment of peripheral vascular disease).<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r2">[2]</xref>&#x000a0;&#x000a0;</p>
        <p>Excess intake of oxalate-containing foods such as nuts (peanuts, cashews, and almonds), spinach, rhubarb, star fruit, chaga mushroom powder, and black iced tea causing oxalate nephropathy have been reported in multiple case reports.<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r16">[16]</xref>&#x000a0;Case reports involving acute ingestions causing oxalate nephropathy often show rapidly improved renal function, suggesting a better prognosis than other causes of oxalate nephropathy.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Alteration of intestinal microbial flora&#x000a0;is also a potential cause of hyperoxaluria.&#x000a0;Commensal gut bacteria such as <italic toggle="yes">Oxalobacter formigenes</italic> and other bacteria can metabolize intestinal oxalate, thus preventing absorption. Antibiotics, such as fluoroquinolones that kill these normal intestinal bacteria, can be associated with an increased risk for oxalate stones and nephropathy. Patients with diabetes and obesity can also have elevated gut oxalate absorption and hyperoxaluria through unclear mechanisms.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref>&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Patients with oxalate nephropathy commonly have precipitating events such as acute dehydration, diuretic use, inflammation, recent antibiotic use, or renin-angiotensin-aldosterone system (RAAS) inhibitors, suggesting a combination of a hyperoxaluria-enabling condition with a precipitating event leading to oxalate deposition causing kidney damage.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p><bold>Enteric hyperoxaluria</bold> occurs in a setting of intestinal bypass surgery or short-bowel syndrome, resulting in calcium-sequestering steatorrhea due to reduced free intestinal calcium, causing increased gastrointestinal oxalate absorption and severe hyperoxaluria.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Usually, dietary oxalate binds to dietary calcium, forming insoluble calcium oxalate, which is excreted in the stool. Conditions that cause fatty acid diarrhea lead to increased binding of fatty acids to dietary calcium, making it unavailable to bind to dietary oxalate. Unbound soluble dietary oxalate gets absorbed into the systemic circulation, increasing oxalate excretion in urine. An intact colon appears to be required for gastrointestinal oxalate absorption.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Oxalate nephropathy and nephrolithiasis were seen in as many as 35% of patients after jejunoileal bypass, associated with increased morbidity, which contributed to the abandonment of that procedure in 1979. It was also seen after the Roux-en-Y gastric bypass procedure. It does not&#x000a0;occur with restrictive weight loss surgeries like gastric sleeve procedures, as the small bowel is not bypassed.<xref ref-type="bibr" rid="article-154870.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Oxalate nephropathy can be seen in chronic pancreatitis, celiac disease, Crohn disease, cystic fibrosis, and with the use of somatostatin analogs.</p>
          </list-item>
          <list-item>
            <p>Drugs like orlistat can cause oxalate nephropathy by impairing fatty acid absorption.</p>
          </list-item>
          <list-item>
            <p>Moderate to severe hypocalcemia can be seen in patients with chronic pancreatitis with oxalate nephropathy, which can be a clue to the diagnosis.<xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
          </list-item>
        </list>
        <p><bold>Calcium phosphate</bold>
<bold>deposition disease</bold> is caused by the development of calcium phosphate crystals within the renal tubules and interstitium, leading to crystalline nephropathy. Calcium phosphate deposition should be especially considered in patients with nephrocalcinosis.</p>
        <p>Differentiation can be seen in microscopic analysis. Calcium phosphate crystals stain blue or red on hematoxylin and eosin (H&#x00026;E) stain, whereas calcium oxalate crystals are translucent. The von Kossa stain&#x000a0;is specific for&#x000a0;phosphate, so it only stains calcium phosphate, not calcium oxalate. Another differentiating feature is that calcium oxalate crystals are birefringent on polarized microscopy.<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;</p>
        <p>Conditions causing hypercalcemia, hypercalciuria, hyperphosphatemia, hyperparathyroidism, hyperphosphaturia, and persistently alkaline urine are the common causes of calcium phosphate deposition.</p>
        <p>Exposure to bowel preparations containing high amounts of phosphate was previously a common cause of calcium phosphate nephropathy, prompting an FDA warning regarding the risk for phosphate nephropathy with sodium phosphate bowel preparations in December 2008, which ultimately led to the voluntary withdrawal of over-the-counter sodium phosphate bowel preparations.<xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r19">[19]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Crystal Deposition Secondary to Metabolic and Inherited Disorders&#x000a0;</bold>
</p>
        <p><bold>2,8-Dihydroxyadenine (2,8 DHA) crystallopathy</bold>&#x000a0;is&#x000a0;an autosomal recessive disorder secondary to the adenine phosphoribosyl transferase enzyme deficiency leading to crystalluria, CKD, and ESRD. The adenine phosphoribosyl transferase enzyme converts the adenine to adenine-phosphate: the lack of this enzyme leads to increased conversion of adenine to 8-hydroxy adenine and 2,8-dihydroxy adenine production through the xanthine oxidase pathway.</p>
        <p>2,8-dihydroxy adenine crystals are highly insoluble in urine, leading to tubular precipitation, crystalluria, recurrent nephrolithiasis, progressive kidney disease, and ESRD.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;2,8 DHA crystals are radiolucent and can easily be incorrectly diagnosed as uric acid stones if not chemically analyzed. 2,8 DHA is also a rare type of crystalline nephropathy, the diagnosis of which is often missed before renal transplantation. Many of these patients are unfortunately only diagnosed with this disease after they develop evidence of posttransplant allograft dysfunction.&#x000a0;</p>
        <p>These crystals are birefringent, reddish-brown, and have a Maltese cross appearance on polarized microscopy. Renal biopsy specimens show intratubular crystals, which are irregular and fan-shaped. They stain brownish green on H&#x00026;E and periodic acid-Schiff, light blue on Trichrome, and positive for silver staining. Pathologists need to differentiate these crystals from calcium oxalate crystals as they have a similar microscopic appearance.</p>
        <p>Patients can develop renal calculi, acute renal injury, and progressive CKD with a delay in diagnosis. This disease has no extrarenal manifestations as these crystals are deposited only in the kidneys. A recent observational study suggests that many patients can have progressive CKD without a history of kidney stones.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r7">[7]</xref><xref ref-type="bibr" rid="article-154870.r20">[20]</xref></p>
        <p><bold>Dent disease and Lowe syndrome</bold> are a&#x000a0;group of X-linked recessive disorders secondary to mutations in CLCN5 and OCRL1 genes leading to Dent disease type 1 and type 2, respectively. A certain percentage have no identifiable gene mutation and are classified as Dent disease 3. X-linked recessive disorders, such as Dent disease and Lowe syndrome, are also associated with hypercalciuria and renal calcium phosphate deposition, causing nephrocalcinosis, progressive renal failure, and, ultimately, ESRD.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Patients can&#x000a0;present with proximal tubulopathy, full-blown Fanconi syndrome, or hypercalciuria. The cause of the hypercalciuria is secondary to a combination of increased calcium absorption and defective proximal tubular calcium uptake. Clinical presentation can be variable, even within the same family.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The initial presentation may include calcium oxalate and calcium phosphate crystalline renal disease (nephrocalcinosis) and can progress to chronic kidney failure and ESRD. Such individuals often have renal phosphate wasting, leading to osteomalacia. Those patients with Dent disease type 2 can present with other signs like hypotonia, cataracts, and intellectual disability.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>Lowe syndrome is another X-linked recessive disorder secondary to a mutation in the OCRL1 gene, similar to Dent disease type 2. Patients develop&#x000a0;proximal tubulopathy, hypercalciuria, phosphaturia, nephrocalcinosis, osteomalacia, progressive renal failure, metabolic acidosis, and ESRD. Patients usually have associated signs such as cataracts, neurologic signs, developmental disability, and hypotonia. These patients tend to have rapid progression of renal failure and rapid development of ESRD.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;</p>
        <p>Treatment is primarily supportive for both diseases, including thiazide diuretic therapy to reduce urinary calcium excretion, oral potassium citrate, phosphate supplementation, and vitamin D repletion.&#x000a0;&#x000a0;</p>
        <p><bold>Cystinosis</bold> is a rare autosomal recessive disorder characterized by lysosomal accumulation of cystine, secondary to defective transport, leading to intracellular crystallization. The disease is caused by a mutation in the CTNS gene, which encodes cystinosin, the lysosomal cystine transporter which moves cystine extracellularly.<xref ref-type="bibr" rid="article-154870.r21">[21]</xref><xref ref-type="bibr" rid="article-154870.r22">[22]</xref>&#x000a0;</p>
        <p>The lack of a functional transporter causes accumulation and crystallization of the cystine within the lysosome, which ultimately causes apoptosis and localized tissue damage.<xref ref-type="bibr" rid="article-154870.r23">[23]</xref>&#x000a0;This disease can manifest in infancy as failure to thrive. A few cases have been shown to occur in adolescence or adulthood. Both infantile and adolescent presentations can occur in different members of the same family.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
        <p>Some patients can develop proximal tubular dysfunction leading to a full-blown Fanconi syndrome, and progressive renal failure and ESRD can occur. It is the most common cause of Fanconi syndrome in children, and screening of newborns is performed in most developed countries. Early initiation with the cystine-depleting&#x02014;therapy cysteamine is key to delaying CKD progression.<xref ref-type="bibr" rid="article-154870.r24">[24]</xref></p>
        <p>Pathology shows cystine crystal accumulation in glomerular podocytes, mesangial cells, interstitial macrophages, and occasionally in tubular cells. Crystals are needle-like, have geometric shapes, and are strongly birefringent on polarized microscopy; these crystals are typically dissolved during processing. The finding of multinucleated podocytes is often helpful in diagnosis.<xref ref-type="bibr" rid="article-154870.r25">[25]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref><xref ref-type="bibr" rid="article-154870.r27">[27]</xref>&#x000a0;New biomarkers for this condition are currently being studied.<xref ref-type="bibr" rid="article-154870.r28">[28]</xref></p>
        <p><bold>Cystinuria</bold> causes urinary cystine stones with characteristic hexagonal-shaped cystine crystals in the urine. Cystine stones can be difficult to see on X-ray as they are relatively radiolucent. They are very hard and relatively resistant to treatment. Cystine urinary crystals are increasingly soluble as the urinary pH increases, so treatment includes raising the urine pH to 7.5 or even 8 using potassium citrate and sodium bicarbonate.<xref ref-type="bibr" rid="article-154870.r29">[29]</xref></p>
        <p>Very high hydration levels are needed to generate the recommended 3 liters of urine production every 24 hours. When simple measures like hydration and alkalinization cannot control cystine crystallization and stone formation, tiopronin is used as a urinary cystine binder, making it far more soluble.<xref ref-type="bibr" rid="article-154870.r29">[29]</xref>&#x000a0;For more information on cystine, cystine stones, and cystinuria, see our companion Statpearls reference article on "Cystinuria."<xref ref-type="bibr" rid="article-154870.r29">[29]</xref></p>
        <p><bold>Uric acid crystal renal deposition</bold>&#x000a0;can cause acute kidney injury, CKD, or nephrolithiasis with obstructive uropathy. Acute urate nephropathy typically presents as oliguric or anuric renal failure, commonly seen in conditions of massive cell destruction such as tumor lysis. Uric acid crystals associated with acute kidney injury are predominantly seen in the renal collecting tubules.</p>
        <p>Uric acid crystals are&#x000a0;dissolvable in formalin-fixed tissue, leading to empty lacunae. Alcohol fixed or frozen section specimens show needle-shaped or rectangular crystals that stain blue with H&#x00026;E and are birefringent on polarized microscopy.<xref ref-type="bibr" rid="article-154870.r30">[30]</xref><xref ref-type="bibr" rid="article-154870.r31">[31]</xref></p>
        <p>Treatment primarily consists of aggressive hydration, urinary alkalinization, and using xanthine oxidase inhibitors or recombinant urate oxidase, which converts the urate to water-soluble allantoin. While both treatment options can be used prophylactically,&#x000a0; recombinant urate oxidase is particularly useful even after the development of acute urate nephropathy. Chronic urate nephropathy is reviewed elsewhere.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r30">[30]</xref><xref ref-type="bibr" rid="article-154870.r31">[31]</xref>&#x000a0;For more information on uric acid urolithiasis, urinary uric acid, and hyperuricemia, see our companion Statpearls reference articles on "Uric Acid Nephrolithiasis," Hyperuricosuria," and "Hyperuricemia."<xref ref-type="bibr" rid="article-154870.r32">[32]</xref><xref ref-type="bibr" rid="article-154870.r33">[33]</xref><xref ref-type="bibr" rid="article-154870.r34">[34]</xref></p>
        <p>
<bold>Paraproteinemia-related Crystal Deposition Diseases&#x000a0;</bold>
</p>
        <p>Dysproteinemia is characterized by the clonal proliferation of immunoglobulins (Igs) or Ig subunits associated with plasma cell neoplastic or B-cell lymphoproliferative disorders. Diagnosis is generally by renal biopsy findings, serum protein electrophoresis, and skin histological examinations.&#x000a0;</p>
        <p>Paraproteinemia-related crystal deposition disease is associated with five major types of renal crystallopathies, which are summarized below.</p>
        <p>
<bold>1. Light Chain Proximal Tubulopathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Glomeruli freely filter free light chains into the tubular lumen, and the filtered light chains are endocytosed by the proximal tubular cells through megalin and cubilin receptors, which become overwhelmed by large amounts of light chains produced in paraproteinemia;&#x000a0;this leads to intracellular crystallization in proximal tubular cells&#x000a0;and light chain proximal tubulopathy.<xref ref-type="bibr" rid="article-154870.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Light chain proximal tubulopathy is characterized by the accumulation and deposition of light chain monoclonal&#x000a0;Igs in the proximal tubular cells, leading to proximal tubular injury and dysfunction. This can cause Fanconi syndrome, characterized by glucosuria, aminoaciduria, uricosuria, and phosphaturia. The proximal tubular changes can be subtle, and some patients may not develop any clinical signs suggesting proximal tubular dysfunction.<xref ref-type="bibr" rid="article-154870.r36">[36]</xref><xref ref-type="bibr" rid="article-154870.r37">[37]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The crystals formed are needle-shaped and weakly birefringent on polarized microscopy. With staining, they appear eosinophilic, red on mason trichrome, and typically pale with PAS. The standard immunofluorescence techniques can often miss these crystals on frozen section specimens as they can be inaccessible to antibody binding.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Improved sensitivity is obtained on formalin-fixed immunofluorescence stains, antigen retrieval techniques, or protease enzyme use. An electron microscopic examination of the proximal tubular cell reveals intracytoplasmic inclusion crystals.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Light chain Fanconi syndrome is commonly associated with smoldering myeloma and monoclonal gammopathy of undermined significance (MGUS); rare cases have also been reported with chronic lymphocytic leukemia and diffuse large B-cell lymphoma.<xref ref-type="bibr" rid="article-154870.r38">[38]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>All crystals causing light chain Fanconi syndrome belong to the K variant light chain, derived from the VK1 sub-group.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of the underlying clonal proliferative disorder is recommended to treat light chain Fanconi syndrome, while plasma exchange has no role in its therapy.<xref ref-type="bibr" rid="article-154870.r39">[39]</xref><xref ref-type="bibr" rid="article-154870.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other recommended treatments include bortezomib, autologous stem cell transplantation, immunotherapy drugs, daratumumab, and renal transplantation.<xref ref-type="bibr" rid="article-154870.r39">[39]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>2. Light Chain Cast Nephropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Light-chain cast nephropathy, also called myeloma cast nephropathy, is the most common variety of paraproteinemia-related renal disorders.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It is characterized by monoclonal light chains admixed with Tamm-Horsfall protein in the thick ascending loop of Henle and deposited in the distal convoluted tubule.&#x000a0;&#x000a0;
<list list-type="bullet"><list-item><p>Excess light chains enter the distal convoluted tubules when the proximal tubular cells are supersaturated and interact with Tamm-Horsfall protein (THP).</p></list-item><list-item><p>Using loop diuretics and the presence of hypercalcemia increases the risk for light chain cast nephropathy by facilitating the interaction between the light chains and the THP.</p></list-item><list-item><p>ACE inhibitor, ARB, and NSAID use also increase the risk of cast nephropathy.<xref ref-type="bibr" rid="article-154870.r41">[41]</xref></p></list-item><list-item><p>Leukocyte activation by the THP contributes to the interstitial inflammation and fibrosis seen in myeloma cast nephropathy.<xref ref-type="bibr" rid="article-154870.r42">[42]</xref>&#x000a0;&#x000a0;</p></list-item><list-item><p>Increased activation of the NF-kB pathway and mitogen-activated protein kinases cause proximal tubular cell injury and necrosis, which leads to further production of inflammatory mediators such as IL-6, IL-8, and TNF-&#x003b2;1.</p></list-item><list-item><p>Increased inflammatory response plays a crucial role in tubular interstitial atrophy and fibrosis.<xref ref-type="bibr" rid="article-154870.r42">[42]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The casts are hypereosinophilic, pale with PAS staining, polychromatic, lamellated with mason trichrome stain, and weakly birefringent on polarized microscopy. They have a hard texture, often fracture when cut with a microtome (leading to sharp or jagged edges), and can have a fractured appearance. On electron microscopy, these casts exhibit sharp edges, geometric shapes, and cellular reactions by tubular epithelial cells, infiltrating leukocytes, and giant cells.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immunofluorescence plays a critical role in diagnosing light chain cast nephropathy;&#x000a0;staining is positive for either Kappa or Lambda chains, with&#x000a0;minimal staining of the opposite light chain.<xref ref-type="bibr" rid="article-154870.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment is aimed at stopping the production of monoclonal immunoglobulins and is&#x000a0;similar to the management of light chain proximal tubulopathy described above.&#x000a0;
<list list-type="bullet"><list-item><p>Rapid lowering of free light chains with chemotherapy has been associated with renal functional recovery and is considered renoprotective.<xref ref-type="bibr" rid="article-154870.r43">[43]</xref>&#x000a0;</p></list-item><list-item><p>Plasma exchange may be of some benefit in this disorder but is controversial and, if used, should be combined with chemotherapy.<xref ref-type="bibr" rid="article-154870.r44">[44]</xref><xref ref-type="bibr" rid="article-154870.r45">[45]</xref>&#x000a0;</p></list-item><list-item><p>The beneficial role of plasmapheresis has not been proven in randomized trials and, therefore, is not currently recommended for the treatment of light chain cast nephropathy.<xref ref-type="bibr" rid="article-154870.r43">[43]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>3. Crystalglobulinemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This rare disorder is associated with paraproteinemia and multiple myeloma, as well as other malignancies, and is characterized by the accumulation of hypereosinophilic extracellular microcrystals of monoclonal proteins primarily within the systemic and renal microvasculature. These microcrystals can cause vascular injury with thrombosis and occlusion, leading to end-organ damage.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients typically present with acute kidney injury, renal failure, albuminuria, arthralgias, and rashes.<xref ref-type="bibr" rid="article-154870.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>On histological examination, eosinophilic crystal deposits are seen within the microvasculature, renal glomeruli, and occasionally in the renal tubules.<xref ref-type="bibr" rid="article-154870.r46">[46]</xref> The crystals have geometric shapes, stain red on trichrome, and pale on PAS. Proliferative glomeruli may show engulfed crystals within the leukocytes and monocytes. IgG Kappa- or Lambda-restricted staining is noted on immunofluorescence.<xref ref-type="bibr" rid="article-154870.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment is aimed at reducing paraprotein production. Plasma exchange is recommended for the rapid removal of these circulating paraproteins.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Data is limited on this rare disease, but the prognosis is generally poor, especially if renal failure is the initial presenting symptom.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r46">[46]</xref></p>
          </list-item>
        </list>
        <p>
<bold>4. Crystal-storing Histiocytosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Crystal-storing histiocytosis is an extremely rare entity associated with B-cell malignancies, such as multiple myeloma, characterized by needed-shaped crystal accumulation of monoclonal immunoglobulins in the histiocytes.<xref ref-type="bibr" rid="article-154870.r47">[47]</xref> These histiocytes are typically found in the bone marrow, and they can also be occasionally seen in extranodal tissues, the&#x000a0;lungs, lymph nodes, skin, stomach, eyes, and kidneys.<xref ref-type="bibr" rid="article-154870.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>This may present about 25% of the time as a localized mass, swelling, or lesion incidentally found on imaging or physical examination that may initially be considered suspicious for cancer.&#x000a0;It can be easily confused with an organ malignancy such as lung cancer.<xref ref-type="bibr" rid="article-154870.r47">[47]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>This entity is the same as monoclonal proximal tubulopathy except that the crystals accumulate in histiocytes rather than in proximal tubular cells. All these crystals also belong to the Kappa variant, derived from the VK1 sub-group.<xref ref-type="bibr" rid="article-154870.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The differential diagnosis includes malakoplakia, Gaucher disease, and rhabdomyoma.<xref ref-type="bibr" rid="article-154870.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment should be aimed at stopping paraprotein production, and plasma exchange is not recommended.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>There are a few case reports of patients having light chain Fanconi syndrome, light chain cast nephropathy, and crystal-storing histiocytosis together. All these patients had a monoclonal kappa neoplasm derived from the VK1 sub-variant.<xref ref-type="bibr" rid="article-154870.r37">[37]</xref><xref ref-type="bibr" rid="article-154870.r48">[48]</xref></p>
        <p>
<bold>5. Light Chain Crystalline Podocytopathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This is also a very rare entity described primarily in case reports and can be associated with other paraprotein-related renal crystalline diseases, such as crystal-storing histiocytosis or light chain proximal tubulopathy.<xref ref-type="bibr" rid="article-154870.r49">[49]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It has been associated with focal and segmental glomerulosclerosis (FSGS), which is thought to be secondary FSGS from podocyte injury stemming from crystal deposition.<xref ref-type="bibr" rid="article-154870.r50">[50]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinical manifestations are related to proteinuria and possible nephrotic syndrome. Monoclonal IgG-&#x003ba; is the most commonly involved paraprotein.<xref ref-type="bibr" rid="article-154870.r50">[50]</xref><xref ref-type="bibr" rid="article-154870.r51">[51]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Similar to other renal crystallopathies, immunofluorescence of the light chains may be negative due to the epitope binding site not being exposed. Staining is improved with antigen exposure techniques.<xref ref-type="bibr" rid="article-154870.r50">[50]</xref><xref ref-type="bibr" rid="article-154870.r49">[49]</xref><xref ref-type="bibr" rid="article-154870.r50">[50]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-induced Renal Crystalline Deposition Diseases</bold>
</p>
        <p>Various medications used in clinical practice can be associated with crystal deposition within the renal tubules and parenchyma, causing renal tubular crystallopathy and acute kidney injury.&#x000a0;Drug-induced crystal deposition diseases commonly occur in the setting of volume depletion, use of higher than recommended dosages, prolonged medication use, and changes in urine pH. All of these can contribute to supersaturation and drug or metabolite precipitation. The pK value of the specific drug is important in determining its crystallization potential.</p>
        <p>Clinicians should consider the potential risk for crystalluria and acute kidney injury with these drugs. A thorough clinical history and examination of the urine sediment are helpful and critical in the diagnosis.&#x000a0;&#x000a0;&#x000a0;</p>
        <p><bold>Acyclovir&#x000a0;</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The higher dose of acyclovir used by the IV route (rather than by mouth) and rapid infusion can cause crystalluria and acute kidney injury.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acyclovir crystals are needle-shaped, birefringent on polarized microscopy, and seen in the renal distal tubules.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoiding rapid infusions of IV acyclovir at higher doses and maintaining adequate hydration helps prevent crystalluria.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Amoxicillin&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin is a commonly used penicillin group antibiotic; it can be associated with crystalline nephropathy. Risk factors for crystallization include a higher dose of the medication, volume depletion, and an acid urine pH.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The crystals are needle or rod-shaped and can form bunches or sheaves. The treatment involves stopping the medication, volume repletion, and urinary alkalization when the urine pH is lower than 6.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>No histological evidence of intrarenal deposits of amoxicillin crystals has been published despite their known association with crystalluria and AKI, like sulfadiazine and sulfamethoxazole.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <p><bold>Ciprofloxacin</bold>&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Ciprofloxacin, a fluoroquinolone antibiotic, can be associated with crystalluria in an alkaline urinary pH setting and with higher antibiotic doses.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ciprofloxacin crystals can assume different shapes and can appear as needles, starbursts, sheaves, tans, and butterflies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Crystals have a lamellar appearance, and they are strongly birefringent on polarized microscopy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Crystalline nephropathy can be prevented by volume repletion, dose adjustment according to renal function, and prevention of urinary alkalization.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <p><bold>Methotrexate&#x000a0;</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Methotrexate can cause renal damage and AKI by various mechanisms, but crystal deposition is the most common cause of acute kidney injury, usually reversible.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk for crystal precipitation is higher in conditions associated with volume depletion, higher doses, and low urinary pH.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methotrexate crystals form annular structures of needle-shaped crystals that stain yellow, golden, or brown on an H&#x00026;E stain. They are strongly birefringent on polarized microscopy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intratubular precipitation is prevented by maintaining high urinary flow and urinary alkalization with sodium bicarbonate or potassium citrate, optimally with a pH greater than 7.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <p><bold>Protease Inhibitors (indinavir, atazanavir, and darunavir)</bold>&#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>All protease inhibitors have been associated with crystalluria and crystalline nephropathy. These drugs precipitate in urine with a pH higher than 3.5.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nephrotoxicity is prevented by discontinuing the drug and maintaining adequate hydration to promote a euvolemic state. Urinary acidification is not recommended to treat crystalluria.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>These drugs can also cause radiolucent stones, which are not visible on non-contrast CT scans or X-rays. Patients taking one of these medications who present with symptoms of renal colic and hydronephrosis require a contrast study to help identify potential medication stones.<xref ref-type="bibr" rid="article-154870.r52">[52]</xref><xref ref-type="bibr" rid="article-154870.r53">[53]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Indinavir is the most studied in this class. Its crystals are translucent, needle-shaped, typically clustered in distal tubules and collecting ducts, associated with monocytic inflammatory infiltration and giant cell reaction. Darunavir crystals are needle-shaped or biconvex and are birefringent on polarized microscopy.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Early recognition of the disease can avoid irreversible renal fibrosis and the development of CKD.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Sulfa Antibiotics&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sulfadiazine is commonly associated with crystalluria, but sulfamethoxazole can also cause urinary crystals, although less commonly.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A higher incidence of sulfadiazine-associated crystalluria has been noted with the increased use of pyrimethamine, a sulfa medication used for toxoplasmosis.<xref ref-type="bibr" rid="article-154870.r54">[54]</xref><xref ref-type="bibr" rid="article-154870.r55">[55]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>These drugs have lower solubility in acidic urine.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulfa crystals have hourglass shapes with prominent radial striations and can have a "sheaves of wheat" appearance. They are birefringent on polarized microscopy and can be deposited in any part of the renal tubules or urinary tract.<xref ref-type="bibr" rid="article-154870.r26">[26]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV hydration and alkalinization of the urine promote the solubility of these crystals and renal recovery.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulfonamide-induced crystalluria and AKI are considered reversible. A renal biopsy may be necessary if there is no improvement in renal function, as these drugs can also cause acute interstitial nephritis.<xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Triamterene&#x000a0;&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Triamterene is a potassium-sparing diuretic commonly used in combination with thiazide diuretics. Crystalluria is common with triamterene, but AKI is rare.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Triamterene precipitates in acidic urine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Its urinary crystals are brown, can form Maltese cross-like structures, and are birefringent on polarized microscopy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It is essential to differentiate these crystals from 2,8 dihydroxyadenine crystals as they appear similar in urine and renal pathology specimens.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref><xref ref-type="bibr" rid="article-154870.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amiloride is an alternative potassium-sparing diuretic that can be substituted for triamterene and&#x000a0;is not associated with&#x000a0;crystalluria or urolithiasis.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-154870.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history, physical examination, complete family history, examination of dietary habits, review of medications, and supplement intake are essential steps when evaluating patients with suspected renal crystallopathy.&#x000a0;</p>
        <p>Patients with primary hyperoxaluria can have recurrent episodes of kidney stones causing abdominal pain, renal colic, hematuria, dysuria, urinary tract infections, or, in children, failure to thrive.<xref ref-type="bibr" rid="article-154870.r56">[56]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary hyperoxaluria should be considered in children with kidney stones or nephrocalcinosis and adults with recurrent calcium oxalate kidney stones along with markedly elevated 24-hour urine oxalate excretion, typically greater than 75 mg.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with primary hyperoxaluria will have recurrent calcium oxalate kidney stones, rapidly progressive CKD, and usually progress to ESRD.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The median onset of ESRD is 5.5 years, and most develop renal failure in the first three decades of life. However, some can have a delayed presentation in adulthood with occasional or recurrent calcium oxalate kidney stones as the only clinical manifestation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with primary hyperoxaluria can have deposition of calcium oxalate crystals in the macula and hyperpigmentation of the retina with or without retinal edema.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some patients can develop oxalate deposition in bones, leading to skeletal malformations and multiple fractures. The presence of a sclerotic band in rapid-growth areas is an early radiological sign of bone oxalosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oxalate crystal precipitation in the bone marrow can cause inflammation and fibrosis, leading to stimulation of extramedullary hematopoiesis. These patients can develop pancytopenia, hepatomegaly, and splenomegaly.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac deposition of calcium oxalate crystals can cause cardiac arrhythmia, heart block, and cardiomyopathy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermal deposition of oxalate crystals can cause subcutaneous nodules, eschar formation, and superficial ulceration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac and dermal manifestations are uncommon in infants, but these can be found in children and adults.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some patients can have neuropathy, hypogonadism, and hypothyroidism.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some patients with primary hyperoxaluria can have vascular deposition of calcium oxalate. Patients with crystaloglobulinemia may have vascular deposition of paraprotein crystals, causing livedo reticularis, acrocyanosis, peripheral gangrene, and ulcerations.</p>
          </list-item>
        </list>
        <p>Individuals with secondary hyperoxaluria and 2,8 DHA crystalline nephropathy can have a history of recurrent nephrolithiasis, progressive chronic kidney disease, and nephrocalcinosis.&#x000a0;Patients with PH2 disease can also have progressive CKD and recurrent calcium oxalate nephrolithiasis, and recent data suggest that these can progress to ESRD, requiring renal transplantation.&#x000a0;</p>
        <p>Progression to CKD/ESRD has yet to be documented with PH3.<xref ref-type="bibr" rid="article-154870.r1">[1]</xref><xref ref-type="bibr" rid="article-154870.r2">[2]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p>
        <p>Patients with cystinosis will accumulate cystine crystals in the renal tubules, contributing to progressive renal dysfunction and ESRD. They can also develop accumulations of cystine in the eyes, bones, thyroid gland, pancreas, gonadal organs, liver, muscles, and brain.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cystine accumulates predominantly in the kidneys and the eyes, primarily found in the cornea, posterior chamber, and retina.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystine accumulation in the thyroid gland can cause atrophic thyroiditis, leading to hypothyroidism; pancreatic deposition of cystine crystals can cause pancreatic insufficiency and diabetes; and muscle accumulation can cause myopathy. Patients with significant myopathy would be at risk for developing aspiration pneumonia and extrapulmonary restrictive lung disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some patients can have cerebral accumulations causing multiple central nervous system symptoms, bone accumulation leading to growth retardation, and multiple fractures.<xref ref-type="bibr" rid="article-154870.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Patients with paraproteinemia can present with fatigue, bone pain, anemia, renal dysfunction, hypercalcemia, increased total serum protein level, lytic bone lesions, and compression/pathological fractures.</p>
        <p>Patients with paraproteinemia-related Fanconi syndrome, cystinosis, Dent disease types 1 and 2, and Lowe syndrome usually demonstrate Fanconi syndrome. They may also present with nephrocalcinosis and hypercalciuria.</p>
        <p>Patients with proximal tubular dysfunction can have episodes of dehydration, volume depletion, metabolic acidosis, hypophosphatemia, and AKI.</p>
        <p>Infants and children with proximal tubular dysfunction can develop failure to thrive, growth retardation, osteomalacia, and bone fractures.</p>
        <p>Patients with crystaloglobulinemia can have cutaneous purpura, peripheral ulcers, mucosal ulcers, erosive polyarthropathy, peripheral neuropathy, peripheral ischemia, renal dysfunction, and rare visceral ischemia.</p>
      </sec>
      <sec id="article-154870.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients with suspected primary hyperoxaluria should receive a 24-hour urine excretion for calcium, phosphorus, magnesium, uric acid, oxalate, citrate, and cystine. Any renal stones should be collected and chemically analyzed.</p>
        <p>Hyperoxaluric patients should have an evaluation to rule out secondary causes of hyperoxaluria. Those with severe hyperoxaluria (&#x0003e;75 mg/day) should undergo genetic testing to confirm the diagnosis of primary hyperoxaluria.&#x000a0;There are also reported cases of hypercalcemia in patients with primary hyperoxaluria.<xref ref-type="bibr" rid="article-154870.r56">[56]</xref><xref ref-type="bibr" rid="article-154870.r57">[57]</xref></p>
        <p>Plasma oxalate levels should be measured in patients with a decline in renal function, especially when the GFR is below 30 mL/min, as the urinary oxalate levels will not be representative. In primary hyperoxaluria patients with ESRD, plasma oxalate levels are typically higher than 80 &#x003bc;mol/L, while in non-primary hyperoxaluria hyperoxaluric patients, the plasma oxalate level may range between 30 &#x003bc;mol/L to 80 &#x003bc;mol/L.<xref ref-type="bibr" rid="article-154870.r58">[58]</xref><xref ref-type="bibr" rid="article-154870.r59">[59]</xref>&#x000a0;</p>
        <p>Spot urine tests for glycolate, glycerate, and 4-hydroxy-2-oxoglutarate have&#x000a0;a high sensitivity, particularly for PH2 and PH3.<xref ref-type="bibr" rid="article-154870.r60">[60]</xref>&#x000a0;</p>
        <p>Genetic testing is the gold standard for diagnosing all types of primary hyperoxaluria; it should be performed in all patients with suspected primary hyperoxaluria (a 24-hour urine oxalate &#x0003e;75 mg in patients without enteric hyperoxaluria), and it also helps estimate the responsiveness to pyridoxine treatment in PH1 patients.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p>
        <p>Systemic levels of oxalate increase once the GFR drops below 30 mL/min, which leads to extrarenal calcium oxalate deposits in other organs, such as the bones, skin, central nervous system, retina, and cardiovascular organs, consistent with systemic oxalosis.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;These patients should get an electrocardiogram, echocardiogram, thyroid function panel, and x-ray examination of the long bones to rule out fractures and radiodense metaphyseal bands.<xref ref-type="bibr" rid="article-154870.r61">[61]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Patients suspected of Fanconi syndrome should undergo microscopic urinalysis and an evaluation for glycosuria in the presence of normal serum glucose levels, aminoaciduria, uricosuria, and phosphaturia. Serum chemistry, calcium, phosphorous, and uric acid levels should be obtained. See our companion StatPearls reference article on "Fanconi syndrome."<xref ref-type="bibr" rid="article-154870.r62">[62]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystinosis is diagnosed by the detection of elevated cystine levels in leukocytes.
<list list-type="bullet"><list-item><p>It can also be diagnosed clinically by detecting corneal cystine crystals on slit lamp examination.</p></list-item><list-item><p>Molecular testing is another well-established test to diagnose cystinosis.</p></list-item><list-item><p>Plasma chitotriosidase enzymatic activity is an excellent predictor of leukocyte cystine levels.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>2,8 DHA crystalline nephropathy, Dent disease types 1 and 2, and Lowe's syndrome can be diagnosed and confirmed by&#x000a0;genetic testing. However, many patients with these conditions do not have detectable mutations, so this is not an exclusionary test.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with suspected paraproteinemia should undergo a complete blood count with differential, a comprehensive metabolic panel including calcium level, serum protein electrophoresis with immunofixation, serum free light chain testing, 24-hour urine for electrophoresis with immunofixation, serum beta -2 microglobulin level, albumin, and LDH. They&#x000a0;should also undergo imaging of the entire skeleton, preferably whole-body, low-dose computed tomography, as a whole-body skeletal survey is less sensitive.<xref ref-type="bibr" rid="article-154870.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Those with an abnormally elevated serum-free light chain immunoglobulin level greater than 500 milligrams/liter should have proteinuria quantification.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with predominantly albuminuria are less likely to have myeloma cast nephropathy but more likely to have&#x000a0;myeloma-induced amyloidosis, light chain deposition disease, and heavy chain deposition disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with excess Bence-Jones proteinuria are at high risk of developing myeloma cast nephropathy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk for myeloma cast nephropathy increases significantly once the daily excretion of Bence-Jones protein exceeds 1 gram.<xref ref-type="bibr" rid="article-154870.r63">[63]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-154870.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p><bold>Primary hyperoxaluria type 1</bold>&#x000a0;(PH1) therapy includes hyperhydration, using calcium oxalate crystallization, thiamine inhibitors, and pyridoxine. Pyridoxine effectively lowers oxalate levels in subgroups of PH1 patients with specific mutant alleles of the AGXT gene.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p>
        <p>Treatment starts with pyridoxine at 5 mg/kg and then measuring urinary oxalate levels to assess the patient's response within two weeks of starting therapy. Patients should have at least a 30% reduction of urinary oxalate levels after three months of treatment to be considered pyridoxine responsive.<xref ref-type="bibr" rid="article-154870.r64">[64]</xref>&#x000a0;About 30% of patients with PH1 will respond to this treatment.<xref ref-type="bibr" rid="article-154870.r65">[65]</xref>&#x000a0;Pyridoxine should be stopped in patients who do not respond. The dosage needs to be titrated in patients who respond to the lowest possible effective dose but may be increased to a maximum of 20 mg/kg.<xref ref-type="bibr" rid="article-154870.r64">[64]</xref><xref ref-type="bibr" rid="article-154870.r66">[66]</xref>&#x000a0;Patients on pyridoxine therapy should be monitored regularly for possible neurotoxicity.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref>&#x000a0;Pyridoxine has no role in the treatment of PH2 and PH3.</p>
        <p>Lumisaran was approved by the FDA in 2020 to treat primary hyperoxaluria type 1; it is an RNA interference (RNAi) agent that degrades the messenger RNA for hepatic glycolate oxidase.&#x000a0;Glycolate oxidase&#x000a0;is an enzyme that converts glycolate to glyoxylate, a precursor for oxalate production. Lumisaran decreases oxalate production by decreasing the amount of glyoxylate available to hepatic cells. It was shown to decrease urinary oxalate excretion by 65% after six months of treatment in the placebo-controlled phase 3 study ILLUMINATE-A; however, no change in eGFR was demonstrated in this short-term study. Similar results were noted in other phase-3 controlled studies, ILLUMINATE-B and ILLUMINATE-C. Early data from all the Lumisaran trials suggest that this drug can significantly decrease the risk of crystalluria and stabilize kidney function.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref><xref ref-type="bibr" rid="article-154870.r25">[25]</xref></p>
        <p>Stiripentol, an anti-epileptic agent, has been found to inhibit lactate dehydrogenase isoenzyme 5, which converts glyoxalate to oxalate. Nedosiran, which blocks the conversion of glyoxalate to oxalate through RNA interference, is being studied in PH1 and PH2 patients. Interestingly, it was shown to be effective only in PH1 patients, as no improvement in oxalate levels was noted in patients with PH2. This is thought to be secondary to the GRHPR enzyme being present in other tissues besides the liver. Liver transplantation may someday be avoided for primary hyperoxaluria patients if these and similar agents prove to be clinically successful.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;Clinicians should remember that liver transplants have no role in decreasing the systemic oxalate load.</p>
        <p>Renal replacement therapy should be considered in CKD stage IV and stage V patients even before the development of uremia to minimize systemic oxalosis. Aggressive hemodialysis should be done pretransplantation to decrease the systemic oxalate load in patients awaiting a renal transplant. Predialysis oxalate levels of 50 to 70 &#x003bc;mol/L should be targeted with aggressive dialysis: high flux and high-frequency hemodialysis should be the modality of renal replacement therapy, and the addition of nocturnal peritoneal dialysis can be considered in selected patients.<xref ref-type="bibr" rid="article-154870.r17">[17]</xref>&#x000a0;</p>
        <p>Liver transplantation is the only known curative treatment for this condition. Patients who progress to CKD require combined liver and kidney transplantation. Ideally, this should be performed prior to the development of systemic oxalosis, as patients with a high systemic oxalate load carry the risk of crystal deposition in the transplanted kidney. In selected cases, continuous renal replacement therapy can be considered to decrease the systemic oxalate load during and immediately post-transplant.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref><xref ref-type="bibr" rid="article-154870.r17">[17]</xref></p>
        <p><bold>Secondary oxalate nephropathy</bold>&#x000a0;treatment hinges on sustaining sufficient hydration to generate more than 2 to 3 liters of daily urine output. Patients should be maintained on a low oxalate, high calcium, low-fat diet. Calcium citrate supplements are given with the most common high oxalate daily meals (usually lunch and dinner) to decrease intestinal oxalate absorption through increased gastrointestinal oxalate-calcium binding. Optimization of urinary crystallization inhibitors, like potassium citrate, is also helpful.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p>Studies done to assess the efficacy of oral Oxalobacter formigenes and other probiotics in decreasing oxaluria did not show improved outcomes. A pilot study of an orally administered recombinant oxalate decarboxylase enzyme (which degrades oxalate), known as reloxilase, has shown promising results in patients with&#x000a0;CKD and is being studied in a larger randomized control trial.<xref ref-type="bibr" rid="article-154870.r67">[67]</xref>&#x000a0;</p>
        <p><bold>Calcium phosphate deposition disease</bold> therapy includes optimized hydration, low sodium intake, potassium citrate supplementation, maintaining a normal calcium diet, and treating the disorder's underlying cause.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref>&#x000a0;</p>
        <p><bold>2,8, DHA crystalluria</bold> treatment involves using a xanthine oxidase inhibitor, such as allopurinol or febuxostat, to overcome the APRT deficiency that causes this disorder.<xref ref-type="bibr" rid="article-154870.r68">[68]</xref>&#x000a0;Both agents effectively reduce 2,8 DHA excretion in patients with an APRT deficiency. A recent study showed that febuxostat is more effective in reducing the excretion of 2,8 DHA than allopurinol. However, both drugs are equally effective in decreasing the progression of&#x000a0;CKD in this disorder.<xref ref-type="bibr" rid="article-154870.r69">[69]</xref></p>
        <p><bold>Cystinosis</bold>&#x000a0;therapy involves life-long oral cysteamine. The drug enhances cystine clearance, the dosing of which is guided by leukocyte cystine levels.<xref ref-type="bibr" rid="article-154870.r22">[22]</xref>&#x000a0;Cysteamine enters the lysosomes and breaks down the cystine into cysteine and cysteine-cysteamine disulfide, which are removed by the cysteine and cysteine-cysteamine transporters, respectively.<xref ref-type="bibr" rid="article-154870.r70">[70]</xref>&#x000a0;</p>
        <p>Cysteamine treatment is not curative, and patients can have progressive renal failure even with long-term therapy. Long-term and early initiation of cysteamine treatment is associated with improvement in renal and extrarenal outcomes. While long-term cysteamine treatment can delay the progression to ESRD, it does not have any significant impact on renal Fanconi syndrome.<xref ref-type="bibr" rid="article-154870.r70">[70]</xref>&#x000a0;Gene therapy treatment is being investigated for the treatment and possible cure of this disease.<xref ref-type="bibr" rid="article-154870.r3">[3]</xref><xref ref-type="bibr" rid="article-154870.r4">[4]</xref></p>
        <p><bold>Cystinuria</bold> causes urinary cystine stones with characteristic hexagonal-shaped cystine crystals in the urine. Cystine stones are very dense and relatively resistant to standard nephrolithiasis treatment such as lithotripsy, so laser therapy is usually preferred.&#x000a0;Cystine urinary crystals are increasingly soluble as the urinary pH increases, so treatment includes raising the urine pH to 7.5 or higher.<xref ref-type="bibr" rid="article-154870.r29">[29]</xref>&#x000a0;Very high hydration levels are needed to generate the recommended 3 liters of urine in 24 hours. Tiopronin is used as a cystine binder, which makes it far more soluble.&#x000a0;For more information on cystine and cystinuria, see our companion Statpearls reference article on "Cystinuria."<xref ref-type="bibr" rid="article-154870.r29">[29]</xref></p>
        <p><bold>Acute urate nephropathy</bold>&#x000a0;therapy primarily consists of aggressive hydration, urinary alkalization, and using xanthine oxidase inhibitors or recombinant urate oxidase, which converts the urate to water-soluble allantoin.&#x000a0;While both treatment options can be used prophylactically, recombinant urate oxidase is particularly useful even after the development of acute urate nephropathy.<xref ref-type="bibr" rid="article-154870.r30">[30]</xref><xref ref-type="bibr" rid="article-154870.r31">[31]</xref></p>
        <p><bold>Multiple myeloma/paraproteinemia</bold>&#x000a0;should be treated initially with supportive care, including hydration, avoidance of nephrotoxic medications, and treatment of any associated anemia or hypercalcemia. All patients with paraproteinemia-related crystalline nephropathy should get standard chemotherapy to reduce monoclonal paraprotein production.</p>
        <p>Standard first-line treatment of newly diagnosed multiple myeloma is the combination of an immunomodulatory drug (lenalidomide), a proteasome inhibitor (bortezomib), and steroids (dexamethasone).<xref ref-type="bibr" rid="article-154870.r71">[71]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Cyclophosphamide or doxorubicin can be used in place of immunomodulatory drugs.<xref ref-type="bibr" rid="article-154870.r72">[72]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Proteasome inhibitors have been shown to improve survival in multiple myeloma across multiple randomized trials and do not require dosage adjustment for renal impairment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Proteasome inhibitors rapidly reduce free light chain concentrations and inhibit the NF-kB inflammatory pathway, thereby decreasing tubular inflammation and apoptosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adding monoclonal anti-CD38 antibodies (daratumumab) to the standard of care has improved the complete remission rates in the GRIFFIN and CASSIOPEIA trials.<xref ref-type="bibr" rid="article-154870.r73">[73]</xref><xref ref-type="bibr" rid="article-154870.r74">[74]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Daratumumab is also an acceptable substitute for patients who cannot tolerate bortezomib for any reason, such as peripheral neuropathy.<xref ref-type="bibr" rid="article-154870.r75">[75]</xref></p>
          </list-item>
        </list>
        <p>Hemodialysis or peritoneal dialysis should be utilized in multiple myeloma patients who demonstrate or develop significant renal failure along with traditional indications such as uremia, hyperkalemia, worsening metabolic acidosis, volume overload, and pericarditis.</p>
        <p>Autologous stem cell transplants&#x000a0;are recommended and should be strongly considered in acceptable patients after 3 to 6 months of induction therapy.<xref ref-type="bibr" rid="article-154870.r9">[9]</xref>&#x000a0;</p>
        <p>Extracorporeal light chain removal has long been entertained as an adjuvant treatment for myeloma cast nephropathy. Therapeutic plasma exchange involves the removal of harmful substances in the plasma. Plasma exchange is also known as single filter plasmapheresis, a modality in which blood is separated into its cellular components and plasma. The plasma with harmful proteins is discarded and replaced with albumin or fresh frozen plasma.</p>
        <p>Two small randomized controlled trials on plasma exchange's role in multiple myeloma have shown conflicting results. The largest randomized controlled trial by Clark et al. had only 97 patients.<xref ref-type="bibr" rid="article-154870.r76">[76]</xref> These patients were randomized into two groups of conventional chemotherapy and plasmapheresis in addition to the standard chemotherapy. The plasmapheresis group had up to 7 plasma exchanges on top of conventional chemotherapy. Plasma exchange was not shown to be beneficial in improving the primary composite outcome of reducing death and promoting renal recovery.&#x000a0;This study has several important limitations as bortezomib chemotherapy was not used in these patients, and they did not have biopsy-confirmed myeloma cast nephropathy.<xref ref-type="bibr" rid="article-154870.r76">[76]</xref></p>
        <p>The use of plasma exchange remains controversial in the treatment of multiple myeloma. Currently, plasma exchange can be considered in patients with severe renal failure and very high levels of Bence-Jones proteinuria, as well as an adjunctive treatment in the management of crystaloglobulinemia.&#x000a0;</p>
        <p>High cut-off hemodialysis has also been suggested as another means of extracorporeal free light chain removal. A dialysis filter with a large-bore size of 10 nm is used with dialysis over weeks to remove free light chain immunoglobulins. HCO-HD (high-cutoff hemodialysis) membrane is capable of removing 90% of free light chains over three weeks and has beneficial effects in a single-center open-label study.<xref ref-type="bibr" rid="article-154870.r77">[77]</xref>&#x000a0;However, multiple randomized trials, such as the Eulite trial, were subsequently conducted to verify this benefit and could not confirm or reproduce these results; therefore, this treatement is not currently recommended.<xref ref-type="bibr" rid="article-154870.r78">[78]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-154870.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of primary hyperoxaluria includes PH2, PH3, hyperparathyroidism, and other causes of nephrocalcinosis as well as all the various causes of secondary hyperoxaluria.&#x000a0;</p>
        <p>The differential diagnosis of cystinosis, Dent disease, and Lowe's syndrome includes other causes of Fanconi syndrome, such as tyrosinemia, galactosemia, glycogen storage diseases, Wilsons disease, hereditary fructose intolerance, multiple mitochondrial disorders causing renal proximal tubular dysfunction, heavy metal toxicity from lead, cadmium, Sj&#x000f6;gren syndrome, multiple myeloma and medications such as tenofovir, ifosfamide, cisplatin, sodium valproate, carbonic anhydrase inhibitors, topiramate, and aminoglycoside antibiotics.</p>
        <p>The differential diagnosis of myeloma cast nephropathy includes amyloidosis, light chain deposition disease, heavy chain deposition disease, membranoproliferative glomerulonephritis, and hypercalcemia-induced&#x000a0;AKI. Crystaloglobulinemia has a differential diagnosis including cryoglobulinemic vasculitis&#x000a0;as well as other paraproteinemias.&#x000a0;</p>
        <p>Drug-induced crystalline nephropathy has a differential diagnosis that includes drug-induced interstitial nephritis, drug-induced tubular toxicity, and acute tubular necrosis.</p>
      </sec>
      <sec id="article-154870.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Primary hyperoxaluria is associated with high morbidity and mortality in infants, but overall mortality has decreased over the past few years. Patients carry a high risk for progression to CKD and ESRD. Unfortunately, many patients tend to have delayed and missed diagnoses; some patients are diagnosed with this disease only after they develop allograft renal dysfunction.<xref ref-type="bibr" rid="article-154870.r56">[56]</xref>&#x000a0;</p>
        <p>Patients with acute ingestion-associated calcium oxalate nephropathy generally have a good prognosis, while those with oxalate nephropathy due to enteric hyperoxaluria generally develop advanced and progressive renal disease.&#x000a0;</p>
        <p>2,8 DHA crystalluria's diagnosis is often delayed and missed. Patients develop recurrent nephrolithiasis, crystalluria, progressive renal failure, and ESRD without appropriate diagnosis and treatment. Many patients are diagnosed with this disease only after they develop allograft renal dysfunction. Sometimes patients are initially diagnosed with uric acid nephrolithiasis based on the radiolucency of 2,8 DHA crystals or are misdiagnosed as calcium oxalate crystallopathy based on the microscopic appearance. Patients with an early, accurate diagnosis and aggressive treatment with high-dose xanthine oxidase inhibitor therapy have a better prognosis and can avoid progression to ESRD.<xref ref-type="bibr" rid="article-154870.r68">[68]</xref><xref ref-type="bibr" rid="article-154870.r69">[69]</xref></p>
        <p>Long-term cysteamine treatment for cystinosis is associated with marked improvement in growth retardation and other endocrine disorders. Cystine accumulation in the brain can be associated with multiple structural brain abnormalities, cognitive impairment, and learning difficulties. Cysteamine treatment also improves multiple neurological symptoms and distal myopathy. This test is usually performed perinatally, and early initiation of treatment and treatment compliance are crucial to optimal outcomes and therapeutic success.<xref ref-type="bibr" rid="article-154870.r23">[23]</xref><xref ref-type="bibr" rid="article-154870.r70">[70]</xref></p>
        <p>Patients with myeloma-related proximal tubular crystalline nephropathy and crystalline histiocytosis have a slowly progressive renal disease and a reasonably good prognosis. These patients often tend to have low-grade multiple myeloma.&#x000a0;The overall prognosis of multiple myeloma has improved significantly over the years.&#x000a0;</p>
        <p>Patients with myeloma cast nephropathy and crystaloglobulinemia tend to have a worse renal prognosis, ultimately requiring long-term renal replacement therapy.&#x000a0;</p>
        <p>Patients with drug-induced crystalluria generally have a good prognosis with renal recovery when there is early identification and termination of the culprit drug. However, a delay in the diagnosis and treatment of drug-induced crystalluria can cause irreversible renal dysfunction.</p>
      </sec>
      <sec id="article-154870.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with primary hyperoxaluria, secondary hyperoxaluria, and 2,8 DHA crystalluria are at increased risk for nephrolithiasis. These patients can develop acute kidney injury, obstructive uropathy causing urosepsis, progressive CKD, and ESRD.</p>
        <p>Patients with PH1 have recurrent calcium oxalate kidney stones, rapidly progressive chronic kidney disease, and can progress to ESRD. The median onset of ESRD is 5.5 years, and most develop renal failure in the first three decades of life. Children with PH1 can develop complications such as growth retardation, failure to thrive, increased fractures, pancytopenia, hypothyroidism, and vascular calcifications leading to arterial insufficiency and heart block. Cardiac and vascular complications are commonly seen in adults.</p>
        <p>Patients with cystinosis, Dent disease types 1 and 2, Lowe syndrome, and paraproteinemia-associated proximal tubular dysfunction can develop Fanconi syndrome.&#x000a0;This has many&#x000a0;concomitant&#x000a0;complications, such as metabolic acidosis, hypophosphatemia, volume depletion, acute kidney injury, and nephrolithiasis. Children with Fanconi syndrome can develop rickets and growth retardation.</p>
        <p>Patients with cystinosis can develop progressive renal failure, ESRD, hypothyroidism, and vacuolar myopathy, contributing to restrictive lung disease and increased risk for aspiration pneumonia, growth retardation, fractures, photophobia, hypogonadism, blindness, and exocrine and endocrine pancreatic insufficiency.<xref ref-type="bibr" rid="article-154870.r79">[79]</xref></p>
        <p>Complications associated with myeloma cast nephropathy include progressive renal failure, multiple other extrarenal complications such as hypercalcemia, anemia, vertebral compression fractures, compressive myelopathy, nerve root compression, peripheral neuropathy, venous thromboembolism, and increased risk for infections.<xref ref-type="bibr" rid="article-154870.r80">[80]</xref></p>
      </sec>
      <sec id="article-154870.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is critically important to optimize outcomes. The importance of compliance with treatment, monitoring, and follow-ups are critical to minimize renal damage. Genetic counseling&#x000a0;is important in many of these disease entities&#x000a0;with&#x000a0;known inheritance patterns.</p>
      </sec>
      <sec id="article-154870.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Crystalline nephropathies are increasingly recognized as a potential cause of progressive&#x000a0;CKD and ESRD. Patient outcomes can be improved by recognizing primary hyperoxaluria as a cause of recurrent calcium oxalate stone disease, oxalate nephropathy, progressive CKD, and ESRD, even in adults. Some of these patients may be candidates for medical therapy with pyridoxine, lumisaran, stiripentol, or nedosiran.<xref ref-type="bibr" rid="article-154870.r16">[16]</xref></p>
        <p>Nephrologists should collaborate with renal pathologists to diagnose patients with adenine phosphoribosyl transferase deficiency causing 2,8- DHA crystalluria and stones resulting in CKD and ESRD, which is treatable with xanthine oxidase inhibitors.<xref ref-type="bibr" rid="article-154870.r81">[81]</xref></p>
        <p>Paraproteinemias cause various types of crystalline nephropathies. The outcomes can be improved with timely diagnosis and treatment, as signs of proximal tubular dysfunction may be the only identifiable clinical manifestation in a patient with paraproteinemia. Oncology input is crucial to the diagnosis of these conditions.</p>
        <p>Patient outcomes can be improved with a thorough history of the patient's dietary habits, timely examination of urine sediment, and close collaboration with nephrologists, primary care physicians, urologists, pediatricians, genetic counselors, oncologists, dietitians, nurses, care coordinators, and renal pathologists in patients suspected of having crystallopathy.&#x000a0;</p>
      </sec>
      <sec id="article-154870.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=154870&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=154870">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/calcium-deposition-and-other-renal-crystal-diseases/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=154870">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/154870/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=154870">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-154870.s15">
        <fig id="article-154870.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Causes of steatorrhea flow sheet Contributed by Prathap Simhadri MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Steatorrhea__causes__flow__chart__slide" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-154870.s16">
        <fig id="article-154870.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Causes of Calcium phosphate deposition flow sheet Prathap Simhadri MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Calcium__phosphate__deposition__causes__slide" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-154870.s17">
        <fig id="article-154870.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Causes of Primary Hyperoxaluria contributed by Prathap Simhadri MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PH__Enzyme__deficiency__slide" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-154870.s18">
        <fig id="article-154870.image.f4" position="float" orientation="portrait">
          <caption>
            <p>These pictures display the calcium oxalate crystals on renal biopsy specimens and light chain crystals on Proximal convoluted tubules Used with permission from Arkanana Pathology Library</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Calcium__oxalate__and__Light__chain__crystals__on__PCT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-154870.s19">
        <fig id="article-154870.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Light chain cast nephropathy slides Used with Permission from Arkana Pathology Library</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Light__chain__cast__nephropathy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-154870.s20">
        <title>References</title>
        <ref id="article-154870.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Joab</surname>
                <given-names>TMJ</given-names>
              </name>
              <name>
                <surname>DeVita</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bijol</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Oxalate nephropathy: a review.</article-title>
            <source>Clin Kidney J</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-204</page-range>
            <pub-id pub-id-type="pmid">35145635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demoulin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gillion</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Morelle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jadoul</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>May</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>717</fpage>
            <page-range>717-727</page-range>
            <pub-id pub-id-type="pmid">34508834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Herlitz</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>The Crystalline Nephropathies.</article-title>
            <source>Kidney Int Rep</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>12</issue>
            <fpage>2942</fpage>
            <page-range>2942-2957</page-range>
            <pub-id pub-id-type="pmid">34901567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herlitz</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Crystalline nephropathies.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>7</issue>
            <fpage>713</fpage>
            <page-range>713-20</page-range>
            <pub-id pub-id-type="pmid">22742545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmonem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>van Dyck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis: a review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <day>22</day>
            <volume>11</volume>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">27102039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowalczyk</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Zisman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Cystinuria: Review of a Life-long and Frustrating Disease.</article-title>
            <source>Yale J Biol Med</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>681</fpage>
            <page-range>681-686</page-range>
            <pub-id pub-id-type="pmid">34970106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Runolfsdottir</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Palsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agustsdottir</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Indridason</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Edvardsson</surname>
                <given-names>VO</given-names>
              </name>
            </person-group>
            <article-title>Kidney Disease in Adenine Phosphoribosyltransferase Deficiency.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-8</page-range>
            <pub-id pub-id-type="pmid">26724837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>1086</fpage>
            <page-range>1086-1107</page-range>
            <pub-id pub-id-type="pmid">35560063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cowan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coffey</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Tuazon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Multiple Myeloma: A Review.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>327</volume>
            <issue>5</issue>
            <fpage>464</fpage>
            <page-range>464-477</page-range>
            <pub-id pub-id-type="pmid">35103762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Faye</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <chapter-title>Vulvodynia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28613543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Militscher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matzkin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lessing</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Abramov</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hyperoxaluria in women with vulvar vestibulitis syndrome.</article-title>
            <source>J Reprod Med</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>500</fpage>
            <page-range>500-2</page-range>
            <pub-id pub-id-type="pmid">16846091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomons</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Melmed</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Heitler</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Calcium citrate for vulvar vestibulitis. A case report.</article-title>
            <source>J Reprod Med</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>879</fpage>
            <page-range>879-82</page-range>
            <pub-id pub-id-type="pmid">1816400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harlow</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Abenhaim</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Vitonis</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Harnack</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Influence of dietary oxalates on the risk of adult-onset vulvodynia.</article-title>
            <source>J Reprod Med</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-8</page-range>
            <pub-id pub-id-type="pmid">18441720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awad-Igbaria</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Palzur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vieira-Baptista</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Changes in the Vaginal Microbiota of Women With Secondary Localized Provoked Vulvodynia.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-344</page-range>
            <pub-id pub-id-type="pmid">35943448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Malieckal</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wanchoo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bijol</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Kidney oxalate crystal deposition in adult patients: A relatively common finding&#x02029;.</article-title>
            <source>Clin Nephrol</source>
            <year>2020</year>
            <month>May</month>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>243</fpage>
            <page-range>243-250</page-range>
            <pub-id pub-id-type="pmid">32101518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperoxaluria</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32644413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groothoff</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Metry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Deesker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garrelfs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Acquaviva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Almardini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cerkauskiene</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferraro</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Groen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mandrile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moochhala</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Prytula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Putnik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rumsby</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bacchetta</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice recommendations for primary hyperoxaluria: an&#x000a0;expert consensus statement from ERKNet and OxalEurope.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-211</page-range>
            <pub-id pub-id-type="pmid">36604599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buysschaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morelle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillion</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jadoul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demoulin</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Etiologies, Clinical Features, and Outcome of Oxalate Nephropathy.</article-title>
            <source>Kidney Int Rep</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>1503</fpage>
            <page-range>1503-1509</page-range>
            <pub-id pub-id-type="pmid">32954074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Alterman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing.</article-title>
            <source>Hum Pathol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>675</fpage>
            <page-range>675-84</page-range>
            <pub-id pub-id-type="pmid">15188133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iwagaitsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nobata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kinashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katsuno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Banno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A case of 2,8-DHA crystalline nephropathy caused by adenine phosphoribosyltransferase deficiency: diagnosis and treatment.</article-title>
            <source>CEN Case Rep</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-334</page-range>
            <pub-id pub-id-type="pmid">36576711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalatzis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cherqui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gasnier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter.</article-title>
            <source>EMBO J</source>
            <year>2001</year>
            <month>Nov</month>
            <day>01</day>
            <volume>20</volume>
            <issue>21</issue>
            <fpage>5940</fpage>
            <page-range>5940-9</page-range>
            <pub-id pub-id-type="pmid">11689434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hohenfellner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zerell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis.</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>240</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-259</page-range>
            <pub-id pub-id-type="pmid">36977426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cherqui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Courtoy</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-131</page-range>
            <pub-id pub-id-type="pmid">27990015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hohenfellner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elenberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nesterova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Newborn Screening: Review of its Impact for Cystinosis.</article-title>
            <source>Cells</source>
            <year>2022</year>
            <month>Mar</month>
            <day>25</day>
            <volume>11</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">35406673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Lumasiran: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-282</page-range>
            <pub-id pub-id-type="pmid">33405070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarlagadda</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced crystal nephropathy: an update.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-58</page-range>
            <pub-id pub-id-type="pmid">18324877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kaskel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Multinucleated podocytes: a diagnostic clue to cystinosis.</article-title>
            <source>Kidney Int</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>10</issue>
            <fpage>1052</fpage>
            <pub-id pub-id-type="pmid">21030980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pennesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peruzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Verrina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goffredo</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Canalini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cassiman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives.</article-title>
            <source>Cells</source>
            <year>2022</year>
            <month>Jun</month>
            <day>04</day>
            <volume>11</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">35681534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nazzal</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Cystinuria</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29262245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>911968</fpage>
            <pub-id pub-id-type="pmid">35909538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>DLN</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Apr</month>
            <day>15</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>6251</fpage>
            <pub-id pub-id-type="pmid">35428828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>KC</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Uric Acid Nephrolithiasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">32809561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperuricosuria</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">32965872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>George</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Minter</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperuricemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">29083565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanders</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of light chain injury along the tubular nephron.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1777</fpage>
            <page-range>1777-81</page-range>
            <pub-id pub-id-type="pmid">22997259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Dysproteinemia and the kidney.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-63</page-range>
            <pub-id pub-id-type="pmid">14676640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.</article-title>
            <source>BMC Nephrol</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <pub-id pub-id-type="pmid">28545410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sapkota</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Non-Hodgkin Lymphoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">32644754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehsan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Salman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Light Chain Deposition Disease: A Systematic Review.</article-title>
            <source>J Hematol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>123</fpage>
            <page-range>123-130</page-range>
            <pub-id pub-id-type="pmid">36118549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Batuman</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>The Proximal Tubule Toxicity of Immunoglobulin Light Chains.</article-title>
            <source>Kidney Int Rep</source>
            <year>2021</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1225</fpage>
            <page-range>1225-1231</page-range>
            <pub-id pub-id-type="pmid">34013100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanders</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Booker</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins.</article-title>
            <source>J Clin Invest</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>570</fpage>
            <page-range>570-6</page-range>
            <pub-id pub-id-type="pmid">2298921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeisberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neilson</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of tubulointerstitial fibrosis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1819</fpage>
            <page-range>1819-34</page-range>
            <pub-id pub-id-type="pmid">20864689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finkel</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Shirali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abudayyeh</surname>
                <given-names>A</given-names>
              </name>
              <collab>American Society of Nephrology Onco-Nephrology Forum</collab>
            </person-group>
            <article-title>Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Dec</month>
            <day>07</day>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>2273</fpage>
            <page-range>2273-2279</page-range>
            <pub-id pub-id-type="pmid">27526708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Plasma exchange for myeloma kidney: cast(s) away?</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>11</issue>
            <fpage>1211</fpage>
            <page-range>1211-3</page-range>
            <pub-id pub-id-type="pmid">18480853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Lust</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Greipp</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Hayman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>11</issue>
            <fpage>1282</fpage>
            <page-range>1282-8</page-range>
            <pub-id pub-id-type="pmid">18385667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>El Ters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kashani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Crystalglobulin-induced nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>525</fpage>
            <page-range>525-9</page-range>
            <pub-id pub-id-type="pmid">25190731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mobarki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papoudou-Bai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dumollard</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Alhazmi</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Musawi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Madkhali</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Muqri</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>P&#x000e9;oc'h</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karpathiou</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Crystal-Storing Histiocytosis: The Iceberg of More Serious Conditions.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>11</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36673081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghiringhelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fisogni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lavazza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molteni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malberti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trombatore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gusolfino</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Varotti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tanzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manotti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Combined renal proximal tubulopathy and crystal storing histiocytosis in a patient with &#x003ba; light chain multiple myeloma.</article-title>
            <source>Pathologica</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-293</page-range>
            <pub-id pub-id-type="pmid">34463673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2145970</fpage>
            <pub-id pub-id-type="pmid">36632756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal light chain crystalline podocytopathy and tubulopathy associated with monoclonal gammopathy of renal significance: a case report and literature review.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>12</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>322</fpage>
            <pub-id pub-id-type="pmid">30419839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eymieux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miquelestorena-Standley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rabot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maisons</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Touchard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Crystalline podocytopathy and tubulopathy linked to kappa light chain deposits in a context of smoldering multiple myeloma.</article-title>
            <source>Clin Kidney J</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>351</fpage>
            <page-range>351-353</page-range>
            <pub-id pub-id-type="pmid">35145650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Calculi, Nephrolithiasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">28723043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r53">
          <label>53</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Renal Colic</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">28613743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Boylen</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Sattler</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Pyrimethamine-sulfadiazine for treating Pneumocystis carinii pneumonia and toxoplasmosis in AIDS.</article-title>
            <source>Clin Pharm</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84, 87</page-range>
            <pub-id pub-id-type="pmid">2645082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Georgiev</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Management of toxoplasmosis.</article-title>
            <source>Drugs</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-88</page-range>
            <pub-id pub-id-type="pmid">7527323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Shalom</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garrelfs</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Groothoff</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Primary hyperoxaluria: the pediatric nephrologist's point of view.</article-title>
            <source>Clin Kidney J</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>Suppl 1</issue>
            <fpage>i23</fpage>
            <page-range>i23-i28</page-range>
            <pub-id pub-id-type="pmid">35592624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>ENDOCRINE MANIFESTATIONS OF PRIMARY HYPEROXALURIA.</article-title>
            <source>Endocr Pract</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>1414</fpage>
            <page-range>1414-1424</page-range>
            <pub-id pub-id-type="pmid">29144803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhasin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000dc;rekli</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Atta</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Primary and secondary hyperoxaluria: Understanding the enigma.</article-title>
            <source>World J Nephrol</source>
            <year>2015</year>
            <month>May</month>
            <day>06</day>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-44</page-range>
            <pub-id pub-id-type="pmid">25949937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Nabhan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Abdelrahman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abdelaziz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Helmy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghanim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bazaraa</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Badr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tolba</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Kotb</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Eweeda</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Fayez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical spectrum of primary hyperoxaluria type&#x000a0;1: Experience of a tertiary center.</article-title>
            <source>Nephrol Ther</source>
            <year>2017</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>176</fpage>
            <page-range>176-182</page-range>
            <pub-id pub-id-type="pmid">28161266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greed</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Willis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belostotsky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Frishberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metabolite diagnosis of primary hyperoxaluria type 3.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1443</fpage>
            <page-range>1443-1446</page-range>
            <pub-id pub-id-type="pmid">29705963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r61">
          <label>61</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Milliner</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Sas</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cogal</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lieske</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <chapter-title>Primary Hyperoxaluria Type 1</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2002</year>
            <month>6</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">20301460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r62">
          <label>62</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Keefe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
            </person-group>
            <chapter-title>Fanconi Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30521293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sathick</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Drosou</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Myeloma light chain cast nephropathy, a review.</article-title>
            <source>J Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-198</page-range>
            <pub-id pub-id-type="pmid">29730782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martin-Higueras</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Inherited conditions resulting in nephrolithiasis.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-283</page-range>
            <pub-id pub-id-type="pmid">31789978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Woerden</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Groothoff</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wijburg</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Annink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wanders</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Waterham</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications of mutation analysis in primary hyperoxaluria type 1.</article-title>
            <source>Kidney Int</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>746</fpage>
            <page-range>746-52</page-range>
            <pub-id pub-id-type="pmid">15253729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>MJG</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of primary hyperoxaluria type 1.</article-title>
            <source>Clin Kidney J</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>Suppl 1</issue>
            <fpage>i9</fpage>
            <page-range>i9-i13</page-range>
            <pub-id pub-id-type="pmid">35592620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grujic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keddis</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kausz</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lieske</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Knauf</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2021</year>
            <month>Apr</month>
            <day>26</day>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <page-range>945-948</page-range>
            <pub-id pub-id-type="pmid">33416876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rashid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Cruz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adenine phosphoribosyl transferase deficiency leads to renal allograft dysfunction in kidney transplant recipients: a systematic review.</article-title>
            <source>J Bras Nefrol</source>
            <year>2022</year>
            <season>Jul-Sep</season>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-416</page-range>
            <pub-id pub-id-type="pmid">35635787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edvardsson</surname>
                <given-names>VO</given-names>
              </name>
              <name>
                <surname>Runolfsdottir</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Sch Agustsdottir</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Oddsdottir</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Eiriksson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palsson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.</article-title>
            <source>Eur J Intern Med</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>48</volume>
            <fpage>75</fpage>
            <page-range>75-79</page-range>
            <pub-id pub-id-type="pmid">29241594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000e9;z&#x000e9;gou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Llinares</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kieffer-Jaquinod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Regan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aupetit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chabli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sagn&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Debacker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chadefaux-Vekemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Journet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gasnier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2012</year>
            <month>Dec</month>
            <day>11</day>
            <volume>109</volume>
            <issue>50</issue>
            <fpage>E3434</fpage>
            <page-range>E3434-43</page-range>
            <pub-id pub-id-type="pmid">23169667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durie</surname>
                <given-names>BGM</given-names>
              </name>
              <name>
                <surname>Hoering</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abidi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kahanic</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Thakuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orlowski</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Barlogie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Feb</month>
            <day>04</day>
            <volume>389</volume>
            <issue>10068</issue>
            <fpage>519</fpage>
            <page-range>519-527</page-range>
            <pub-id pub-id-type="pmid">28017406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Hari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Callander</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Noga</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Turturro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rifkin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Estevam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>May</month>
            <day>10</day>
            <volume>119</volume>
            <issue>19</issue>
            <fpage>4375</fpage>
            <page-range>4375-82</page-range>
            <pub-id pub-id-type="pmid">22422823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voorhees</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Laubach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sborov</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silbermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Nathwani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Efebera</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Holstein</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jakubowiak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wildes</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Orlowski</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Shain</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lutska</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ukropec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoehn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Aug</month>
            <day>20</day>
            <volume>136</volume>
            <issue>8</issue>
            <fpage>936</fpage>
            <page-range>936-945</page-range>
            <pub-id pub-id-type="pmid">32325490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perrot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnulf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Belhadj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Benboubker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>B&#x000e9;n&#x000e9;</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Zweegman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caillon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caillot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Corre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delforge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dejoie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doyen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Facon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sonntag</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fontan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jie</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Karlin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kuhnowski</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leleu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Macro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orsini-Piocelle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roussel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stoppa</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>van de Donk</surname>
                <given-names>NWCJ</given-names>
              </name>
              <name>
                <surname>Wuill&#x000e8;me</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Broijl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Touzeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tiab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marolleau</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Meuleman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vekemans</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Westerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Offner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Escoffre-Barbe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eveillard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Garidi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmadi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krevvata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kampfenkel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vanquickelberghe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Avet-Loiseau</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sonneveld</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1378</fpage>
            <page-range>1378-1390</page-range>
            <pub-id pub-id-type="pmid">34529931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Facon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Plesner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Orlowski</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bahlis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Quach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>O'Dwyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perrot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venner</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Weisel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mace</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Raje</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tiab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Macro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frenzel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leleu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ahmadi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Rampelbergh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uhlar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tromp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delioukina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1582</fpage>
            <page-range>1582-1596</page-range>
            <pub-id pub-id-type="pmid">34655533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sternbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Heidenheim</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>DN</given-names>
              </name>
              <collab>Canadian Apheresis Group</collab>
            </person-group>
            <article-title>Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>06</day>
            <volume>143</volume>
            <issue>11</issue>
            <fpage>777</fpage>
            <page-range>777-84</page-range>
            <pub-id pub-id-type="pmid">16330788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutchison</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bradwell</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basnayake</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Chappel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foggensteiner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Adu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cockwell</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-54</page-range>
            <pub-id pub-id-type="pmid">19339414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutchison</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cockwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moroz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bradwell</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Fifer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jesky</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Storr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wessels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winearls</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Weisel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heyne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.</article-title>
            <source>Lancet Haematol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>e217</fpage>
            <page-range>e217-e228</page-range>
            <pub-id pub-id-type="pmid">30872075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesterova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis: the evolution of a treatable disease.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-9</page-range>
            <pub-id pub-id-type="pmid">22903658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Falco</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-46</page-range>
            <pub-id pub-id-type="pmid">25031979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-154870.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaffer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biyani</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Adenine Phosphoribosyltransferase Deficiency: A Rare Cause of Recurrent Urolithiasis.</article-title>
            <source>J Endourol Case Rep</source>
            <year>2017</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-51</page-range>
            <pub-id pub-id-type="pmid">28466077</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
